<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366439">
  <stage>Registered</stage>
  <submitdate>22/07/2014</submitdate>
  <approvaldate>14/08/2014</approvaldate>
  <actrnumber>ACTRN12614000874617</actrnumber>
  <trial_identification>
    <studytitle>Investigating the effects of a high DHA fish oil supplement on cognitive performance in older adults with Mild Cognitive Impairment: A 12-month randomised, double-blind, placebo controlled trial based in Wellington, New Zealand
</studytitle>
    <scientifictitle>In older adults with mild cognitive impairment, do omega-3 fatty acids compared to a placebo improve cognitive performance?</scientifictitle>
    <utrn> U1111-1157-4846</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Mild Cognitive Impairment</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Studies of normal psychology, cognitive function and behaviour</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>12 month intervention of 1500 mg of docosahexaenoic acid (DHA) and 300 mg of eicosapentaenoic acid (EPA) per day. Participants will take 3 x 500mg of DHA+100mg of EPA capsules in the morning with breakfast every day for 12 months. Participants will be given 4 bottles of capsules (each containing 200 capsules) at the end of the baseline testing session, another bottle at the end of the 2nd session and the final bottle at the end of the 3rd testing session. Participants will be required to return the capsule bottles with all unused capsules to the following testing sessions.</interventions>
    <comparator>Sunflower oil. Participants will take 3 capsules in the morning with breakfast for 12 months.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Behaviour</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of cognitive improvement or decline using the following battery of tests:: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Californina Older Adult Stroop Test (COAST), the Coin Rotation Task (CRT), the Trail Making Test A and B (TMT), the National Adult Reading Test (NART) and the Digit Span backwards test (DSBT) from the Weschler Adult Intelligence Scale 3 (WAIS-III).</outcome>
      <timepoint>Participants will be tested on the cognitive tests at baseline, after 6 and 9 months of taking the supplements and lastly a final testing session after 12-months at end of the trial.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in well-being measures: Geriatric Depression Scale (GDS) SF-36 Short Form 36 and  the Geriatric Anxiety Inventory (GAI).</outcome>
      <timepoint>Participants will be tested on the cognitive tests at baseline, after 6 and 9 months of taking the supplements and lastly a final testing session after 12-months at end of the trial.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in weight. Tested using a digital scale. </outcome>
      <timepoint>Baseline testing session and at the final testing session after 12-months at the end of the trial.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood pressure. Tested using a digital sphygmomanometer.</outcome>
      <timepoint>Baseline testing session and at the final testing session after 12-months at the end of the trial.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Presence or absence of APOE 4 gene by way of a blood sample using polymerase chain reaction analysis.</outcome>
      <timepoint>At the final testing session after 12-months at the end of the trial.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria for participants will be a diagnosis of cognitive impairment based on neuropsychological assessment and self-reporting. Agree to not start taking own fish oil supplement during the 12-month trial.
.</inclusivecriteria>
    <inclusiveminage>60</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Major medical conditions including head injury or recent major surgery, problem swallowing capsules, consumption of 3 more more servings of oily fish per week, consumption of fish oil supplements in the last 12 months and an allergy to fish or seafood.

</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealed when it was done by central randomisation by computer.</concealment>
    <sequence>Random allocation using computer software.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>4 repeat testing sessions at baseline, after 6 months and 9 months of taking the supplements and lastly a final testing session after 12-months at end of the trial

This study will require a minimum of 50 older adults with Mild Cognitive Impairment, 25 participants in each capsule group. This sample-size calculation was based on a small effect size of 0.25, also a difference in z score of 0.5 and to prove a statistical power equal to 0.99 at a a level of 0.05 (2 tailed). Allowing for an attrition rate of 16% based on previous studies, an initial sample of 65 participants will be required to give sufficient power to detect the primary effects. </statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/10/2014</anticipatedstartdate>
    <actualstartdate>1/12/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate>31/05/2016</actualenddate>
    <samplesize>65</samplesize>
    <actualsamplesize>72</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate>31/07/2017</anticipatedlastvisitdate>
    <actuallastvisitdate>31/07/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Alexia Mengelberg</primarysponsorname>
    <primarysponsoraddress>Massey University
Wallace Street 
Mt Cook 
Wellington 6021 
New Zealand</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Massey University Wellington</fundingname>
      <fundingaddress>Wallace Street 
Mt Cook 
Wellington 6021 
New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Neurological Foundation</fundingname>
      <fundingaddress>66 Grafton Rd, Grafton 1010, New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Oakley Mental Health Foundation</fundingname>
      <fundingaddress>PO Box 302499
North Harbour
Auckland 0751
 </fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Hope-Selwyn Foundation Scholarship in Ageing Research</fundingname>
      <fundingaddress>PO Box 32082, Devonport, Auckland 0744</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study design: 12-month randomised, double-blind, placebo-controlled intervention trial with 4 measurement points. 
Participants: 72 men &amp; women, aged 60-90 years with Mild Cognitive Impairment. 
Intervention: Half the participants will receive fish-oil capsules and the other half will receive placebo capsules for 12 months. 

Outcome measures: cognitive performance, well-being, blood pressure and weight. 
Demographic and nutritional data will be collected as covariates.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
PO Box 5013
Wellington 6011</ethicaddress>
      <ethicapprovaldate>28/10/2014</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>14/08/2014</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Miss</title>
      <name>Alexia Mengelberg</name>
      <address>Massey University Wellington 
PO Box 756 
Wellington 6140 
New Zealand</address>
      <phone> +64 04 801 5799 ext. 63844</phone>
      <fax />
      <email>alexiamengelberg@gmail.com</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Alexia Mengelberg</name>
      <address>Massey University Wellington 
PO Box 756 
Wellington 6140 
New Zealand</address>
      <phone> +64 04 801 5799 ext. 63883</phone>
      <fax />
      <email>alexiamengelberg@gmail.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Alexia Mengelberg</name>
      <address>Massey University Wellington 
PO Box 756 
Wellington 6140 
New Zealand</address>
      <phone> +64 04 801 5799 ext. 63844</phone>
      <fax />
      <email>alexiamengelberg@gmail.com</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>